ClinicalTrials.gg
Not yet recruitingNCT07378293[Statins]Updated Jan 30, 2026

Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers

A Phase 1 interventional study of Simvastatin (10mg, 20mg, 40mg) and Rosuvastatin (5mg, 20mg, 40mg) in Diabete Mellitus and Lipid Profile, sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper. Not yet recruiting at 2 sites in Pakistan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing simvastatin in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Simvastatin · Diabetes Mellitus.

Planned enrollment
5th of 10
100 · median 95
Started
2026
the only one that year
Phase 1
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Shaheed Benazir Bhutto University Sheringal Dir Upper

Among the 11 studies testing simvastatin in Diabetes Mellitus, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 1, and was the 11th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 11 studies testing simvastatin in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing simvastatin in Diabetes Mellitus, or all of them as a file.
02

Study summary

This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy volunteers. The study will assess changes in fasting blood glucose, insulin, and C-peptide levels following two days of statin administration under controlled conditions. The research seeks to provide comparative data on the potential diabetogenic effects of these medications.

Read the detailed description

This study addresses emerging evidence suggesting statin therapy may modestly increase diabetes risk in a dose-dependent manner. The trial will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. Blood glucose will be measured using standardized glucometers, while insulin and C-peptide levels will be determined using ELISA assays. The study aims to clarify whether different statins have varying effects on glucose metabolism during short-term exposure and to establish dose-response relationships.

03

Conditions studied

  • Diabete Mellitus
  • Lipid Profile

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteers
  • Non diabetic
  • blood glucose level (less than140 mg/dl)

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of diabetes mellitus
  • With chronic diseases e.g heart disease, kidney disease
  • participants taking other medications
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Rosuvastatin (5mg, 20mg, 40mg)

    The assigned participants will be given Rosuvastatin 5mg, 20mg, 40mg OD for two days

    Drug: Rosuvastatin (5mg, 20mg, 40mg)

  • Experimental
    Atorvastatin (10mg,20mg, 40mg)

    The assigned participants will be given Atorvastatin 10mg,20mg, 40mg OD for two days

    Drug: Atorvastatin (10mg, 20mg, 40mg)

  • Experimental
    Simvastatin (10mg, 20mg, 40mg)

    The assigned participants will be given Simvastatin 10mg, 20mg, 40mg OD for two days

    Drug: Simvastatin (10mg, 20mg, 40mg)

Interventions

  • DrugSimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

    Also known as: Simvastatin

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

    Also known as: Rosuvastatin

  • DrugAtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

    Also known as: Atorvastatin

06

What researchers measure

Primary outcomes

  1. Blood Glucose Measurements

    Blood glucose of the subjects will be determined by glucometer in mg/dl

    Time frame: before dosing and 2 days after dosing

  2. Insulin Levels Determination

    Blood insulin levels of each participants will be checked by using human insulin ELISA kit 96 wells on respective peak plasma concentration of respective statin

    Time frame: Before dosing and two days after dosing

  3. C- Peptide determination

    Blood samples approx. 4 mL will be taken from the participants to check C- Peptide levels by using human peptide C ELISA kit on respective peak plasma concentration of respective statin

    Time frame: Before dosing and after two days of Dosing

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The study results will be shared in Journals without the participant identifiers.

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 76 non-industry phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 55. This study's planned 9 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 30, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 20, 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07378293
Lead sponsor
Shaheed Benazir Bhutto University Sheringal Dir Upper
Collaborators
Khyber Medical University Peshawar
Responsible party
Dr Abid Ullah (Lecturer, Shaheed Benazir Bhutto University Sheringal Dir Upper) — Principal investigator
First posted
Jan 30, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Dr Abid Ullah, PhD
Contact
abid@sbbu.edu.pk
+92 302 8533155
Dr Abid Ullah, PhD
principal investigator · Shaheed Benazir Bhutto University,sheringal

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simvastatin · Rosuvastatin · Atorvastatin

Start the discussion